Hematopoietic growth factors: Personalization of risks and benefits

Citations of this article
Mendeley users who have this article in their library.


A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed. © 2012 Federation of European Biochemical Societies.




Puhalla, S., Bhattacharya, S., & Davidson, N. E. (2012). Hematopoietic growth factors: Personalization of risks and benefits. Molecular Oncology. John Wiley and Sons Ltd. https://doi.org/10.1016/j.molonc.2012.03.001

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free